Cargando…

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy

BACKGROUND: Current availability of several biologic treatments for severe asthma makes it possible to choose the most appropriate for each patient. Sometimes a good percentage of patients with severe asthma may be eligible for biologics that target either the allergic phenotype or the eosinophilic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carpagnano, Giovanna Elisiana, Pelaia, Corrado, D’Amato, Maria, Crimi, Nunzio, Scichilone, Nicola, Scioscia, Giulia, Resta, Onofrio, Calabrese, Cecilia, Pelaia, Girolamo, Quarato, Carla Maria Irene, Foschino Barbaro, Maria Pia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268123/ https://www.ncbi.nlm.nih.gov/pubmed/32482128 http://dx.doi.org/10.1177/1753466620929231

Ejemplares similares

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study
por: Campisi, Raffaele, et al.
Publicado: (2023)

Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2020)

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
por: Pelaia, Corrado, et al.
Publicado: (2021)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
por: Pelaia, Corrado, et al.
Publicado: (2021)

Adherence to omalizumab: A multicenter "real-world" study
por: Campisi, Raffaele, et al.
Publicado: (2020)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
por: Scioscia, Giulia, et al.
Publicado: (2020)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
por: Pelaia, Corrado, et al.
Publicado: (2023)

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis
por: Di Bona, Danilo, et al.
Publicado: (2021)

Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab
por: Carpagnano, Giovanna E, et al.
Publicado: (2019)

High Level of Blood Eosinophils and Localization of Bronchiectasis in Patients with Severe Asthma: A Pilot Study
por: Quaranta, Vitaliano Nicola, et al.
Publicado: (2023)

A survey of fungal microbiota in airways of healthy volunteer subjects from Puglia (Apulia), Italy
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2019)

Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma
por: Maglio, Angelantonio, et al.
Publicado: (2021)

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study
por: Nolasco, Santi, et al.
Publicado: (2023)

Can Leukotriene Receptor Antagonist Therapy Improve the Control of Patients with Severe Asthma on Biological Therapy and Coexisting Bronchiectasis? A Pilot Study
por: Quaranta, Vitaliano Nicola, et al.
Publicado: (2022)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
por: Crimi, Claudia, et al.
Publicado: (2020)

Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region
por: Resta, Emanuela, et al.
Publicado: (2022)

Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2022)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
por: Pelaia, Corrado, et al.
Publicado: (2017)

The Role of Airways 17β-Estradiol as a Biomarker of Severity in Postmenopausal Asthma: A Pilot Study
por: Scioscia, Giulia, et al.
Publicado: (2020)

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype
por: Lacedonia, Donato, et al.
Publicado: (2017)

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness
por: Pelaia, Corrado, et al.
Publicado: (2018)

Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective
por: Caminati, Marco, et al.
Publicado: (2023)

Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2021)

Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients
por: Lacedonia, Donato, et al.
Publicado: (2021)

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
por: Crimi, Claudia, et al.
Publicado: (2023)

MicroRNA expression profile during different conditions of hypoxia
por: Lacedonia, Donato, et al.
Publicado: (2018)

Switching Biological Therapies in Severe Asthma
por: Scioscia, Giulia, et al.
Publicado: (2023)

Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2021)

Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program
por: Campisi, Raffaele, et al.
Publicado: (2021)

Surgical Mask and N95 in Healthcare Workers of Covid-19 Departments: Clinical and Social Aspects
por: Gelardi, Matteo, et al.
Publicado: (2020)

Molecular Targets for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Exhaled Nitric Oxide and Exhaled Breath Temperature as Potential Biomarkers in Patients with Pulmonary Hypertension
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2018)

Body mass index, airflow obstruction, dyspnea, and exercise index is not modified after 6 months therapy with roflumilast in a cohort of patients with chronic obstructive pulmonary disease
por: Dragonieri, Silvano, et al.
Publicado: (2016)

Update on optimal use of omalizumab in management of asthma
por: Pelaia, Girolamo, et al.
Publicado: (2011)

Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
por: Pelaia, Corrado, et al.
Publicado: (2022)

Exhaled Breath Temperature Home Monitoring to Detect NSCLC Relapse: Results from a Pilot Study
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2022)

Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lq6nj2fv676a6qrkvlk48orl4l